END-STAGE KIDNEY DISEASE
Clinical trials for END-STAGE KIDNEY DISEASE explained in plain language.
Never miss a new study
Get alerted when new END-STAGE KIDNEY DISEASE trials appear
Sign up with your email to follow new studies for END-STAGE KIDNEY DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could help kidney transplant patients avoid rejection
Disease control Not yet recruitingThis study tests if a new drug called siplizumab can safely prevent kidney transplant rejection better than the current standard treatment. About 120 adults receiving a kidney transplant will be split into three groups: two groups get different doses of siplizumab, and one gets t…
Matched conditions: END-STAGE KIDNEY DISEASE
Phase: PHASE2 • Sponsor: Nefro Avillion Clinical Development, LLC • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Can a salt substitute help dialysis patients? new study aims to find out
Disease control Not yet recruitingThis study tests whether a potassium-containing salt substitute is safe for people with end-stage kidney disease who are on hemodialysis. Twenty participants will try the salt substitute and regular table salt for 16 days each, with a break in between. Researchers will monitor po…
Matched conditions: END-STAGE KIDNEY DISEASE
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Dialysis showdown: which blood thinner works best?
Knowledge-focused Not yet recruitingThis study looks at two ways to prevent blood clots during dialysis in people with end-stage kidney disease. Twenty adults will try both methods—one using standard heparin and the other using a citrate-based approach—to see which causes less inflammation and removes waste better.…
Matched conditions: END-STAGE KIDNEY DISEASE
Phase: NA • Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:54 UTC
-
New drug CSL300 tested in dialysis patients – safety first
Knowledge-focused Not yet recruitingThis early-stage study tests a drug called CSL300 (Clazakizumab) in 24 Chinese adults with end-stage kidney disease who are on dialysis. The main goal is to see how the drug moves through the body and if it is safe. Participants will receive either the drug or a placebo, and rese…
Matched conditions: END-STAGE KIDNEY DISEASE
Phase: PHASE1 • Sponsor: CSL Behring • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:06 UTC